Program Information
Debate: To Measure Or Not to Measure
J Moran1*, M Miften2*, (1) Univ Michigan Medical Center, Ann Arbor, MI, (2) University of Colorado School of Medicine, Aurora, CO
Presentations
WE-A-BRE-1 Wednesday 7:30AM - 9:30AM Room: Ballroom ERecent studies have highlighted some of the limitations of patient-specific pre-treatment IMRT QA measurements with respect to assessing plan deliverability. Pre-treatment QA measurements are frequently performed with detectors in phantoms that do not involve any patient heterogeneities or with an EPID without a phantom. Other techniques have been developed where measurement results are used to recalculate the patient-specific dose volume histograms.
Measurements continue to play a fundamental role in understanding the initial and continued performance of treatment planning and delivery systems. Less attention has been focused on the role of computational techniques in a QA program such as calculation with independent dose calculation algorithms or recalculation of the delivery with machine log files or EPID measurements.
This session will explore the role of pre-treatment measurements compared to other methods such as computational and transit dosimetry techniques. Efficiency and practicality of the two approaches will also be presented and debated.
The speakers will present a history of IMRT quality assurance and debate each other regarding which types of techniques are needed today and for future quality assurance. Examples will be shared of situations where overall quality needed to be assessed with calculation techniques in addition to measurements. Elements where measurements continue to be crucial such as for a thorough end-to-end test involving measurement will be discussed. Operational details that can reduce the gamma tool effectiveness and accuracy for patient-specific pre-treatment IMRT/VMAT QA will be described. Finally, a vision for the future of IMRT and VMAT plan QA will be discussed from a safety perspective.
Learning Objectives:
1. Understand the advantages and limitations of measurement and calculation approaches for pre-treatment measurements for IMRT and VMAT planning
2. Learn about the elements of a balanced quality assurance program involving modulated techniques
3. Learn how to use tools and techniques such as an end-to-end test to enhance your IMRT and VMAT QA program
Funding Support, Disclosures, and Conflict of Interest: J.M. Moran receives research funding from Blue Cross Blue Shield of Michigan and Varian.
Handouts
- 90-23295-333462-103143.pdf (J Moran)
- 90-25284-339462-103143.pdf (J Moran)
- 90-25285-339462-103132.pdf (M Miften)
Contact Email: